IonQ (NYSE:IONQ) recently achieved significant breakthroughs in quantum computing, including the first simulation of neutrinoless double-beta decay and a major milestone in protein folding, which align with the broader trend of rising tech stocks. The company's stock surged by 92% over the last quarter, benefiting from positive market conditions as the S&P 500 and Nasdaq reached all-time highs. In addition, IonQ's alliances with industry leaders like AstraZeneca and AWS to enhance drug development processes may have supported this robust gain, making the company's advancements particularly relevant against a backdrop of tech sector optimism.

We've discovered 5 weaknesses for IonQ (1 can't be ignored!) that you should be aware of before investing here.

Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

Over the last three years, IonQ's total shareholder return, including share price appreciation and dividends, experienced a very large increase. This substantial growth far surpassed the US Tech industry’s 4.5% decline over the past year, indicating a strong performance relative to the sector. The stock's recent surge aligns with IonQ's advancements in quantum computing and strategic partnerships, as outlined in the introduction, suggesting that these developments may bolster its revenue and earnings forecasts despite current unprofitability.

IonQ's stock is trading at a slight discount to consensus analyst price targets as of today, which raises questions about potential market misalignment or anticipation of future growth. While the company's revenue is projected to grow by 40.22% annually, earnings are expected to decline by 2.2% per year over the next three years, indicating ongoing challenges in achieving profitability. The company’s strategic initiatives, such as collaborations with AstraZeneca and AWS, may contribute to long-term growth potential, but the market seems cautious given the current valuation.

Assess IonQ's previous results with our detailed historical performance reports.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com